| Title |
First-in-human intraoperative near-infrared fluorescence imaging of glioblastoma using cetuximab-IRDye800
|
|---|---|
| Published in |
Journal of Neuro-Oncology, April 2018
|
| DOI | 10.1007/s11060-018-2854-0 |
| Pubmed ID | |
| Authors |
Sarah E. Miller, Willemieke S. Tummers, Nutte Teraphongphom, Nynke S. van den Berg, Alifia Hasan, Robert D. Ertsey, Seema Nagpal, Lawrence D. Recht, Edward D. Plowey, Hannes Vogel, Griffith R. Harsh, Gerald A. Grant, Gordon H. Li, Eben L. Rosenthal |
| Abstract |
Maximizing extent of surgical resection with the least morbidity remains critical for survival in glioblastoma patients, and we hypothesize that it can be improved by enhancements in intraoperative tumor detection. In a clinical study, we determined if therapeutic antibodies could be repurposed for intraoperative imaging during resection. Fluorescently labeled cetuximab-IRDye800 was systemically administered to three patients 2 days prior to surgery. Near-infrared fluorescence imaging of tumor and histologically negative peri-tumoral tissue was performed intraoperatively and ex vivo. Fluorescence was measured as mean fluorescence intensity (MFI), and tumor-to-background ratios (TBRs) were calculated by comparing MFIs of tumor and histologically uninvolved tissue. The mean TBR was significantly higher in tumor tissue of contrast-enhancing (CE) tumors on preoperative imaging (4.0 ± 0.5) compared to non-CE tumors (1.2 ± 0.3; p = 0.02). The TBR was higher at a 100 mg dose than at 50 mg (4.3 vs. 3.6). The smallest detectable tumor volume in a closed-field setting was 70 mg with 50 mg of dye and 10 mg with 100 mg. On sections of paraffin embedded tissues, fluorescence positively correlated with histological evidence of tumor. Sensitivity and specificity of tumor fluorescence for viable tumor detection was calculated and fluorescence was found to be highly sensitive (73.0% for 50 mg dose, 98.2% for 100 mg dose) and specific (66.3% for 50 mg dose, 69.8% for 100 mg dose) for viable tumor tissue in CE tumors while normal peri-tumoral tissue showed minimal fluorescence. This first-in-human study demonstrates the feasibility and safety of antibody based imaging for CE glioblastomas. |
X Demographics
The data shown below were collected from the profiles of 35 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 14 | 40% |
| United Kingdom | 2 | 6% |
| Spain | 1 | 3% |
| India | 1 | 3% |
| Colombia | 1 | 3% |
| Canada | 1 | 3% |
| Mexico | 1 | 3% |
| Unknown | 14 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 24 | 69% |
| Scientists | 5 | 14% |
| Science communicators (journalists, bloggers, editors) | 3 | 9% |
| Practitioners (doctors, other healthcare professionals) | 3 | 9% |
Mendeley readers
The data shown below were compiled from readership statistics for 101 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 101 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 22 | 22% |
| Student > Bachelor | 14 | 14% |
| Student > Master | 11 | 11% |
| Researcher | 10 | 10% |
| Other | 6 | 6% |
| Other | 11 | 11% |
| Unknown | 27 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 21% |
| Biochemistry, Genetics and Molecular Biology | 13 | 13% |
| Chemistry | 11 | 11% |
| Engineering | 7 | 7% |
| Neuroscience | 4 | 4% |
| Other | 15 | 15% |
| Unknown | 30 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 22. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 June 2022.
All research outputs
#1,566,678
of 24,076,257 outputs
Outputs from Journal of Neuro-Oncology
#71
of 3,090 outputs
Outputs of similar age
#35,103
of 333,178 outputs
Outputs of similar age from Journal of Neuro-Oncology
#2
of 96 outputs
Altmetric has tracked 24,076,257 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,090 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 333,178 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 96 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.